Act tessera twitter11/16/2023 ![]() The biomedical postdoc shortage is becoming a problem, yet not one as challenging as the biology and chemistry that many postdocs grapple with. You can follow along at postdocs by recognizing their worth Krishna Yeshwant, Managing Partner at Google Ventures. Isaac Kohane, Editor in Chief, as well as Dr. NEJM AI will be published online only once a month and will also include a bi-monthly newsletter and podcast called “NEJM AI Grand Rounds Podcast.” The list of editors is an impressive bunch including Dr. NEJM AI will provide reviews, policy perspectives, and accessible educational material targeted at practicing physicians and clinician leaders interested in applying AI, computer scientists seeking to translate algorithmic advances to clinical practice, and policymakers and regulators.” This past week, the publisher of the New England Journal of Medicine (NEJM) announced the upcoming launch of NEJM AI, which will “identify and evaluate state-of-the-art applications of artificial intelligence to clinical medicine. We desperately need reform in the antibiotics market to meet what will become a dire need. One that shouldn’t be taken lightly given that the last truly original class of antibiotics was discovered in the 1980s and the number of resistant strains keeps increasing. ![]() That being said, antibiotic resistance is a growing problem. If profit is volume multiplied by price, the antibiotics market suffers from a lack of sufficient amounts of both. They aren’t the first pharma outfit to make this switch in the last couple of years. J&J just announced that they were exiting the antibiotics market, shutting down what appears to be rather underdeveloped programs, and laying off staff. For several years, pharmaceutical companies have been shifting focus away from antibiotic development to more economically favorable markets such as oncology and even rare disease. Some studies quote that the payout for a successful antibiotic drug averages around $47M, which is nowhere near the amount necessary to justify a >$1B investment in creating that drug. It’s long been known that the bacterial antibiotic market is far from favorable. In a recent blog post, Natalie Ma touches on a very important issue-the lack of drug development happening in antibiotics. ![]() The Bacterial Antibiotics Pipeline: Still Broken, No Fix in Sight
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |